Educational Workshops

Lunch Workshop 1
Room Auditorium 500 – 13.00/14.00

TITLE: Revolutionizing diagnostics: Enter a new dimension in mass spectrometry
CHAIR: Dr. Dusanka Kasapic,

Affiliation: Medical Affairs Lead (Roche Diagnostics)
SPEAKER 1: Prof. Dr. Robert De Jonge
Affiliation: VU University Medical Center, Amsterdam, Netherlands
SPEAKER 2: Prof. Dr. Michael Vogeser
Affiliation: Ludwig-Maximilians-University Munich (LMU), Germany
SPEAKER 3: Prof. Dr. Pieter Vermeersch
Affiliation: University of Leuven, Belgium

PROGRAMME:
The workshop will feature a panel of experts who will share their experiences, insights and data from the multicenter evaluation study, discussing how the system performs in daily routine use.

Learning Objectives:
The primary objective of this event is to inform laboratory professionals and clinicians about the strengths and challenges of a fully automated LC-MS/MS analyzer and to foster an understanding of the role of mass spectrometry technology in the routine clinical laboratory.
Abstract: Steroid and therapeutic drug concentrations can be measured using immunoassays and chromatographic methods, such as liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). LC-MS/MS is regarded as the gold standard due to its high sensitivity, specificity, and ability to quantify multiple compounds without cross-reactivity. However, LC-MS/MS faces challenges due to a lack of automation, requiring specialized staff, extensive hands-on time, potential handling errors, and considerable inter-laboratory variation affecting standardization. The pursuit for measuring new and established biomarkers with higher specificity, sensitivity, and accuracy is propelling advancements and innovations in laboratory medicine. Consequently, mass spectrometry has become increasingly used and well-established, particularly in endocrinology and therapeutic drug monitoring, complementing traditional chemistry and immunochemical methods. Although partial automation and commercial kits have enhanced LC-MS/MS’s practicability, it remains less efficient than fully automated immunoassays that offer continuous random access and require no specialized personnel or equipment. The CobasⓇ Mass Spec solution (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) aims to provide a notable improvement as a fully automated LC-MS/MS analyzer, integrating sample extraction and parallel testing through liquid chromatography cartridges, thus enabling random access and higher throughput.
Disclaimer: Cobas i 601 analyzer and Ionify Steroids 1 reagent pack are CE-marked. Further Ionify reagents are still under development. These products are not cleared or available for use in the US. COBAS and IONIFY are trademarks of Roche.

Lunch Workshop 2
Room A – 13.00/14.00

TITLE: AI-Empowered Diagnostic Workflows for Modern Hematology Laboratories
CHAIR: Dr. Fabrizio Papa

Affiliation: Department of Laboratory Sciences, Ospedale Isola Tiberina – Gemelli Isola, Rome, Italy
SPEAKER 1: Dr. Chloe Rampon
Affiliation: Hematology Laboratory, Centre Hospitalier Universitaire de Dijon, Dijon, France
SPEAKER 2: Prof. Marie Christine Béné
Affiliation: Faculty of Medicine, Nantes University, Nantes, France

PROGRAMME
-13.00-13.05: Welcome and Introduction of the topic and speakers – F. Papa
-13.05-13.30 Enhancing Hematology Malignancy Screening with Advanced Hematology Analyzers and Morphology Analysis – C. Rampon
-13.30-13.55 Advancing Platelet Solutions with AI and Morphology Driven Workflows Integrating Four Counting Technologies. – M.C. Béné
-13:55-14:00 Q&A and close

Learning Objectives:
This workshop highlights the practical applications of AI-powered diagnostic workflows in hematology laboratories. Attendees will explore how advanced hematology and morphology analyzers, combined with artificial intelligence, support accurate and efficient diagnostics. Key topics include screening hematologic malignancies, improving platelet counting, and evaluating the performance of modern technologies in diverse clinical contexts.
Through expert-led sessions, participants will learn about the clinical significance of these advancements and how they can be effectively implemented to enhance laboratory practices.

• Explore AI Applications: Understand how AI-powered technologies are applied in hematology laboratories to improve diagnostic accuracy and workflow efficiency.
• Compare Platelet Counting Technologies: Analyze the performance and clinical utility of various PLT counting methods in different clinical settings.
• Enhance Malignancy Screening: Learn about advanced hematology analyzers and their role in improving sensitivity and specificity in hematologic malignancy screening.
• Understand Workflow Integration: Examine how AI-driven morphology analysis and other tools are integrated into laboratory workflows to optimize diagnostics.
• Apply Clinical Insights: Gain practical knowledge on implementing these technologies to address real-world challenges in hematology laboratories.

Lunch Workshop 3
Room B – 13.00/14.00

TITLE: Innovation in neurology patient management: Blood-based biomarkers and the role of Neurofilament Light Chain (NfL) in relapsing multiple sclerosis (RMS)

CHAIR: Dr. James Freeman
Affiliation: Siemens Healthineers
SPEAKER 1: Henrik Zetterberg, MD, PhD
Affiliation: University of Gothenburg, University College London
SPEAKER 2: Jean-Louis Bayart
Affiliation: Clinique St-Pierre, Ottignies, Cliniques Universitaires Saint-Luc
SPEAKER 3: Vincent van Pesch, MD, PhD
Affiliation: Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain)

PROGRAMME
• Intro: Dr. James Freeman(5 minutes)
• Advancement of blood-based biomarkers in neurologic conditions (25 minutes)
• Introduction of NfL as the first CE-marked* blood-based biomarker for RMS (25 min)
• Extro: Dr. James Freeman (5 minutes)
*CE 0197

Learning Objectives:
• Gain a comprehensive understanding of the current and future neurologic blood-based biomarkers.
• Understanding the integration of NfL into laboratory practice and the clinic for RMS.

Lunch Workshop 5
Room 1123 – 13.00/14.00

TITLE: Hematology in the Clinical Laboratory – Technologies Past, Present and Future
CHAIR: Jordan Feder

Affiliation: Scopio Labs, VP Business Development
SPEAKER 1: Dr. Mathias Bruegel
Affiliation: Institute of Laboratory Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany

PROGRAMME
-13.00 – 13.05 Introduction by the Chair
-13.05 – 13.50 Presentation – Dr. M. Bruegel
-13.50 – 14.00 Q&A

Learning Objectives:
The major expectation from the hematology clinical laboratory is to perform an accurate analysis of complete blood count and to reliably identify pathological patient samples with a need for further diagnostic escalation. Until now, the central applied technologies are automated hematology analyzers for automated cell counting and identification of pathological samples, and manual microscopy for confirmation of automated results. In this context, manual microscopy is still the groundbreaking element. Digital AI-supported imaging platforms have been introduced into routine diagnostics in recent years with the aim of reducing labor-intensive and time-consuming manual microscopy. However, beside affecting workflows in the clinical laboratory, these technologies might also have the potential to develop new diagnostic strategies by recognizing cellular patterns in the future that are not accessible to current technologies or the human eye.
This workshop will give an overview of the different technologies applied in hematology routine laboratories. In this context, preliminary validation data of the newly introduced Scopio X100HT digital imaging platform will be presented.

Educational Workshop 1
Room Auditorium 500 – 14.30/15.30

TITLE: Power up your haemostasis lab: Your path to better haemostasis care
CHAIR: Dr Andreas R. Rechner

Affiliation: Scientific Marketing Manager, Haemostasis Sysmex Europe
SPEAKER 1: Priv. Doz. Dr Florian Prüller
Affiliation: FA for Medical and Chemical Laboratory Diagnostics LKH-University Hospital Graz Clinical Institute of Medical and Chemical Laboratory Diagnostics – Graz, Austria
SPEAKER 2: Danielle White
Affiliation: Clinical scientist Addenbrooke’s hospital – Cambridge – United Kingdom
SPEAKER 3: Thomas Pitchford, PhD
Affiliation: Senior Biomedical Scientist – Thrombophilia and Sysmex Consultancy Lead Sheffield Haemophilia and Thrombosis – Sheffield, United Kingdom

PROGRAMME:
-14:30 – 14:35: Introduction – Dr Andreas Rechner
-14:35 – 14:50: Clinical utility of automated light transmission aggregometry in the diagnosis of inherited platelet function disorders – Priv. Doz. Dr Florian Prüller
-14:50 – 15:05: Go with the flow: flow cytometry assay for inherited platelet disorders – Danielle White 
-15:05 – 15:20: Comparison of commercial anti-Xa assay – Thomas Pitchford
-15:20 – 15:30: All Q&A

Learning objectives:
• Understand relevance of inherited platelet function disorders in clinical practice
• Learn how to screen for and how to diagnose inherited platelet function disorders
• Know the differences and commonalities of commercially available anti-Xa assays

Educational Workshop 2
Room A – 14.30/15.30

TITLE: High volume and multidisciplinary workflow integration of infectious disease assays: Experiences from University Hospital of Grenoble and University of Naples Federico II

CHAIR: Dr. James Freeman

Affiliation: Siemens Healthineers
SPEAKER 1: Dr. Carole Chirica
Affiliation: University Hospital of Grenoble
SPEAKER 2: Professor Giuseppe Portella
Affiliation: University of Naples Federico II

PROGRAMME:
Speaker 1: Demonstrating workflow benefits in incorporating infectious disease immunoassays with routine and STAT assays in a high-volume biochemistry lab operating 24/7 – 25 Minutes

Learning Objectives:
1. Successful integration of HIV, HAV, HBV, HCV and Syphilis immunoassays in high-volume workflow biochemistry lab with 24/7 service for organ donations screening
2. Proven turnaround time (TAT) improvement achieved by consolidation of biochemistry and immunoassays assays on new analyzers.
3. Improvements in the lab operational efficiency and optimizing lab staff allocation to meet hospital needs.

Speaker 2: Multidisciplinary automated workflow for routine and screening tests in virology laboratory – 25 Minutes
Learning Objectives:
1. Benefits of integration of multidisciplinary technology (i.e., immunochemistry and nephelometry to optimize virology laboratory routine high-volume workflow)
2. Solutions to efficiently manage reflex test of HBV, HDV Ab, and HIV
3. Optimization solutions for consolidation of virological screening program and routine assays workload

Educational Workshop 3
Room B – 14.30/15.30

TITLE: Best QC Practices for Superior Instrumentation: Achieving High-Quality Outcomes for All
CHAIR: Anna Ruzhanskaya, PhD

Affiliation: Scientific Marketing Manager, Beckman Coulter
SPEAKER: Sten Westgard
Affiliation: Director, Westgard QC, Inc., Madison, WI, USA

PROGRAMME:
-Opening – 5 mins
–S. Westgard “The Value of Sigma Metrics in Laboratory Medicine” – 40 mins
-Q&A – 15 mins

Learning Objectives: Performance requirements around the world are changing. In the US, CLIA’s new acceptability criteria took effect January 1st, 2025, reducing the goals for many common assays from 20% to 40%, with some additional extreme reductions reaching as high as 60%. Biochemistry, immunoassay, and hematology tests are all impacted. For EFLM goals, the new minimums are still proving hard to hit. Even newly proposed goals for uncertainty are no easier—and in many cases, even harder—to achieve. As labs face greater challenges in passing proficiency testing (PT), they face additional expenses as well as significantly greater time and energy to process PT specimens and troubleshoot when PT failures occur. As lab goals tighten, all labs may need to perform more Quality Control (QC), more rules, more levels, even more frequency of running QC.

During the workshop, we will share the mathematics to determine the risk of failing EQA/PT, as well as exactly how much and how often to run QC is readily available – both can be easily summarized by Six Sigma benchmarking. We will discuss instruments and methods that are fine and compliant today and share assumptions about which methods must be revisited. Conventional wisdom about which instruments are “the best” is about to be turned on its head.
• Locate performance requirements for EQA and PT from sources worldwide
• Identify which goals have changed for 2025
• Calculate an analytical Sigma metric
• Evaluate the risk of failing EQA/PT through the analytical Sigma metric
• Determine how much QC (rules, levels, and frequency) are needed based on the analytical Sigma metric
• Grade the success and failure rates of instruments in achieving global analytical goals.

Educational Workshop 5
Room 1123 – 14.30/15.30

TITLE: POCT in Laboratory Medicine: The Added Value and Potential Challenges

CHAIR: Prof. Khosrow Adeli
Affiliation: Past President, International Federation of Clinical Chemistry (IFCC) – Head & Professor, Pediatric Laboratory Medicine, The Hospital for Sick Children (SickKids), University of Toronto, Canada
SPEAKER 1: Prof. Damien Gruson
Affiliation: Chair of Emerging Technology Division, IFCC – Head of the Department and Medical Biochemistry, Department of Clinical Laboratory, Cliniques Universitaires Saint Luc, Brussels, Belgium
SPEAKER 2: Prof. Sergio Bernardini
Affiliation: Secretary General , IFCC – Professor, Department of Internal Medicine & Department of Clinical Biochemistry, University of Rome “Tor Vergata.” – Head of Department, Laboratory, University Hospital TOR Vergata – Roma

PROGRAMME:
-14:30 – 14:35: Opening Remarks by Chair – K. Adeli
-14:35 – 15:00: The Role of Laboratory Medicine in Enhancing Primary Care Efficiency: Can POCT Become a Game-Changer? – D. Gruson
-15:00 – 15:25: The Value of POCT in Urgent Care: Enhancing Speed and Accuracy in Critical Decisions – S. Bernardini
-15:25 – 15:30: Q&A and Discussion

Learning Objectives:
1. Understand the significance of laboratory medicine in enhancing primary care workflows and explore how POCT can improve diagnostic speed and patient outcomes in primary care settings.
2. Explore the role of POCT (e.g., Troponin, NT-proBNP, CRP, PCT) in improving decision-making and outcomes in urgent care.
3. Discuss real-world scenarios and best practices for integrating POCT into primary and emergency care workflows.

Educational Workshop 7
Room A – 16.00/17.00

TITLE: Challenges and innovations in traumatic brain injury care
CHAIR: Dr Christos Varounis, Area Medical Director EMEA

Affiliation: Abbott Core Diagnostics Medical Affairs
SPEAKERS 1 and 2:
Dr Maria Pia Ruggieri, Director of the Emergency Room Unit and Short Stay Unit
Affiliation: A.O San Giovanni Addolorata hospital, Rome, Italy
Prof Ettore Capoluongo, Director of Clinical Pathology Unit
Affiliation: A.O San Giovanni Addolorata hospital, Rome, Italy
SPEAKER 3: Dr Dolores Fuentes Garcia
Affiliation: Hospital Universitario Virgen de las Nieves, Granada, Spain

PROGRAMME:
-16:00: Welcome and introduction – Dr Christos Varounis
-16:10: Bridging the gap: How Health Technology Innovations Can Shape the Management of TBI
• Insights from the ED – Dr Maria Pia Ruggieri
• Insights from the Lab – Prof Ettore Capoluongo
-16:30: Innovating TBI care: enhancing efficiency in the Emergency room – Dr Dolores Fuentes Garcia
-16:50: Live Q&A session – all

Learning Objectives:
Around 2.5 million patients are diagnosed with traumatic brain injury (TBI) in Europe every year. Most of these cases are classified as mild, and only around 10% are likely to have any intracranial lesions visible on a computed tomography (CT) scan. However, CT scan is routinely used in evaluation of these patients, leading to many unnecessary scans being conducted. Therefore, novel blood biomarkers have been developed which can aid in reducing unnecessary costs, mitigating potentially unnecessary radiation exposure, and alleviating strained resources through improved management of patients with suspected mild TBI. The learning objectives are the following:
• Understand current challenges in mild TBI assessment and management in the Emergency Department (ED)
• Gain insight into new, innovative laboratory TBI solutions and the role of the ED and laboratory data in overcoming related challenges.
• Learn from pioneering centers that have already implemented novel TBI testing into patient care pathways in the real world

Educational Workshop 8
Room B – 16.00/17.00

TITLE: The EXENT System: An Innovative Mass Spectrometry solution for Monoclonal Gammopathy assessment

CHAIR: Jamie Ashby, PhD, Sr Manager, Research & Development
Affiliation: The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK
SPEAKER 1: Louis Nevejan, Resident Pharmacist & Clinical Biologist
Affiliation: AZ Sint Jan Brugge, Belgium
SPEAKER 2: Dr. Noemí Puig, MD, PhD, Consultant Physician
Affiliation: Hospital Universitario de Salamanca, Spain

PROGRAMME:
-Part 1 (20 minutes): Speaker: Louis Nevejan
Implementation of the EXENT System for routine clinical use, a step towards a gel-free laboratory!
-Part 2 (20 minutes): Speaker: Dr. Noemí Puig
Understanding the clinical value of the mass spectrometry in the management of patients with monoclonal gammopathies
-Q&A session (20 minutes)

Learning Objectives:
Key learning objectives- to understand
1. Intro: Need for change in monoclonal gammopathy testing
2. Verification of the EXENT System into a routine lab
3. Analytical and clinical value of the EXENT system.

Educational Workshop 10
Room 1123 – 16.00/17.00

TITLE: Novel Diagnostic Strategies to Address Unmet Clinical Needs in a Near-Patient Setting

CHAIR: Prof. Khosrow Adeli
Affiliation: Chair of the Scientific Programme Committee in Brussels and IFCC past President

SPEAKER 1: Caolán Vaughan
Affiliation: Randox Clinical Immunoassay R&D Team Leader
SPEAKER 2: Sophie McColgan
Affiliation: Randox Biosciences Clinical Collaboration Leader

PROGRAMME:
The two speakers will both be speaking on the title of the workshop to convey the learning objectives outlined below.

Learning Objectives:
• Current diagnostic solutions have excessive turnaround times which delay diagnosis and treatment. Recent advancements have introduced innovative novel pathways to enhance clinical intervention. Randox patented Biochip Array Technology enables rapid, simultaneous detection of multiple biomarkers from a single sample. This data-driven risk stratification allows earlier clinical intervention at the patient bedside, to inform personalised treatment pathways. These novel strategies to patient management reduce costs, shorten treatment times, and improve patient outcomes.

Lunch Workshop 4 – EDUW4 – EDUW9
Room C – 13.00/17.00

TITLE: INSIGHTS ON THE LABORATORY MEDICINE

Session One
CHAIR 1: Dr. Zesemdorj Otgon-Uul
Head, Department of Clinical Laboratory, Mongolian National University of Medical Sciences (MNUMS), Mongolia
SPEAKER 1: Prof. Tomris Ozben
Affiliation: IFCC, President – EFLM, Past President – Full Professor of Medical Biochemistry Akdeniz University, Medical Faculty, Dept. of Medical Biochemistry, Antalya Turkey – University of Modena and Reggio Emilia, Medical Faculty, Clinical and Experimental Medicine, Ph.D. Program, Modena, Italy
SPEAKER 2: Prof. Katell Peoc’h
Affiliation: President of the French Society of Clinical Biology – University of Paris, UFR of Medicine of Xavier Bichat, INSERM BIGR 75015 – Assistance publique des Hopitaux de Paris
SPEAKER 3: Prof. Dalius Vitkus
Affiliation: Vilnius University, Associate Professor – Vilnius University Hospital Santaros Klinikos, Head of the Centre of Laboratory Medicine – European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), Member-at-large of the Executive Board – Lithuanian Society of Laboratory Medicine, President
SPEAKER 4: Prof. Sanja Stankovic
Affiliation: President of Serbian Society for Clinical Laboratory Medicine and Science (SCLM) – Director of Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia – EuSpLM, FESC

Session Two
CHAIR 2: Prof. Klaus Peter Kohse
Affiliation: Professor of Clinical Chemistry and Pathobiochemistry, University Medicine Oldenburg – Past-Dean of Education, Faculty of Medicine, University of Oldenburg – Treasurer, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
SPEAKER 5: Prof. Mario Plebani
Affiliation: President of the European Federation of Laboratory Medicine (EFLM) – Honorary Professor of Clinical Biochemistry and Clinical Molecular Biology – Past-Dean of the Medical School of the University of Padova, Italy – Editor in Chief of the Journal CCLM and Diagnosis (Dx) – Adjunct Professor, Department of Pathology, University of Texas, Medical Branch, Galveston, USA
SPEAKER 6:Prof. Giuseppe Banfi
Affiliation: Scientific Director, IRCCS Istituto Ortopedico Galeazzi, Milan – Clinical Biochemistry, University of San Raffaele, Milano – Scientific Ambassador Milano Innovation District
SPEAKER 7: Prof. Issam Frigaa
Affiliation: Head of Hemobiology and Blood Bank Center, Mustapha University Hospital, Algiers – President of Scientific Council of National Blood Agency, Algeria – President of the National Commission of Technical Experts, NBA – Professor, University of Health Sciences, Algiers
SPEAKER 8: Prof. Myrna Germanos Haddad
Affiliation: Saint Joseph University of Beirut – President of the Syndicate of Biologists of Lebanon – President of the National Accreditation Committee
SPEAKER 9: En. Mohd Hareeff Bin Muhammed
Affiliation: Head of Ambulatory, Allied Health & Ancillary Services, IHH Healthcare Malaysia – Chief Executive Officer, Premier Integrated Labs Sdn Bhd, IHH Healthcare – Consultant, Center for Healthy Ageing & Wellness (H-CARE), University Kebangsaan Malaysia – Adjunct Professor, Faculty of Allied Health, Universiti Kebangsaan Malaysia – Malaysian Allied Health Professions Council (MAHPC)

PROGRAMME:

SESSION ONE

-13:00-14:45 – Chair – Dr. Zesemdorj Otgon-Uul
-13:05-13:30 Shaping the Future of Laboratory Medicine: Current Innovations, and Emerging Trends – Prof. Tomris Ozben
-13:30-13:55 Current Challenges in Exploring Iron Metabolism in 2025 – Prof. Katell Peoc’h
-13:55-14:20 Analytical Performance Specifications for External Quality Assessment – Prof. Dalius Vitkus
-14:20-14:45 Clinically Accepted Biomarkers for HCC: Focus on PIVKA-II – Prof. Sanja Stankovic

SESSION TWO

-14:45-16:55 – Chair – Prof. Klaus Peter Kohse
-14:50-15:15 New Insights in Laboratory Automation – Prof. Mario Plebani
-15:15-15:40 Consensus Statement on Vitamin D: Whys, Whens and Hows – Prof. Giuseppe Banfi
-15:40-16:05 Management of the Iron Deficiency in Blood Donor: New Approaches – Prof. Issam Frigaa
-16:05-16:30 Elimination of Viral Hepatitis and HIV: an Achievable Goal – Prof. Myrna Germanos Haddad
-16:30-16:55 Sustainable Diagnostics: The Future of Humanity – En. Mohd Hareeff Bin Muhammed

Learning Objectives:

• Main advantages and future trends of automation in laboratory medicine.
• Interpreted main mechanisms and molecular actors of iron metabolism.
• Recognize strengths and limitations of good biomarkers in iron deficiency biological diagnosis.
• General principals of EQA according to ISO 15189:2022
• How to understand analytical performance specifications (APS) for EQA/PT
• Clinical relevance of APS for EQA/PT
• Main biomarkers results in pathological conditions.
• Clinical application of PIVKA-II in diagnosis, surveillance and prognosis of HCC.
• Define epidemiology & diagnosis of HCC, listing current and emerging biomarkers for HCC.
• Identify key advancements in laboratory medicine and evaluate the impact of technologies such as total laboratory automation, molecular diagnostics on clinical practice.
• Overview the role of Artificial Intelligence, digitalization, and integrated diagnostics in medical laboratory operations, diagnosis and treatment.
• Learn value based healthcare in laboratory medicine.
• To know appropriateness and Accuracy of vitamin D measurement.
• Understand the main advantages of automation in laboratory medicine
• Understanding new development in total automation
• Improve knowledge on future trends in laboratory automation
• Knowing the main mechanisms and molecular actors of iron metabolism
• Choosing the good biomarkers for iron deficiency biological diagnosis, knowing their strengths and limitations
• Interpreting the main biomarkers results in pathological conditions

Lunch Workshop 6
Room Auditorium 500 – 13.00/14.00

TITLE: Empowering women’s health: challenges and solutions
CHAIR: Dr Liza Kunz, System Director Endocrinology and Reproductive Medicine

Affiliation: Abbott Core Diagnostics Medical Affairs
SPEAKER 1: Prof Nurgül Keser, Professor in Cardiology
Affiliation: Health Sciences University Faculty of Medicine Department of Cardiology, Istanbul, Türkiye
SPEAKER 2: Dr Carole Cummins, Research Fellow/Honorary Associate Professor
Affiliation: Sandwell and West Birmingham NHS Trust /Dept of Applied Health Sciences, University of Birmingham, UK

PROGRAMME:
-13:00 Welcome and introduction – Dr Liza Kunz
-13:10 Women’s Heart, Unique Challenges: Exploring Sex-Specific Cardiovascular Care – Prof. Nurgül Keser
-13:30 Advocating for better health in women with ovarian cancer: improving diagnostic pathways – Dr Carole Cummins
-13:50 Live Q&A session – all

Learning Objectives:
Empowering women’s health is crucial for advancing overall healthcare outcomes. This workshop will address two pivotal areas: cardiovascular care and ovarian cancer. We will delve into the unique challenges women face in cardiovascular health, emphasizing sex-specific symptoms, risk factors, and treatment approaches. Additionally, we will explore the challenges in diagnosing and treating ovarian cancer, highlighting novel perspectives and advancements in diagnosis. A key focus will be on the role of innovative biomarkers in improving diagnosis and treatment for both cardiovascular conditions and ovarian cancer. Attendees will gain insights into the latest research and strategies to improve women’s health outcomes.

The learning objectives are the following:
• Understand sex-specific cardiovascular care including symptoms, risk factors, and recent research findings.
• Recognize current challenges in diagnosing ovarian cancer, discuss novel perspectives and advancements in ovarian cancer care
• Explore recent advancements in biomarker research including clinical applications and advocacy for better health in women

Lunch Workshop 7
Room A – 13.00/14.00

TITLE: Component-resolved diagnostics in allergy – The next step towards personalized patient management.

CHAIR: James Dowd
Affiliation: Siemens Healthineers
SPEAKER 1: Dr. Marco W.J. Schreurs
Affiliation: Microvida
SPEAKER 2: Dr. Johannes Grosch
Affiliation: Siemens Healthineers

PROGRAMME:
-13:00-13:40 – Introduction to component-resolved diagnostics – Understanding the clinical advantages
-13:40-14:00 – Peanut components in practice – Diagnosing peanut allergies with confidence

Learning Objectives:
• Differentiate between allergen extracts and allergen components by understanding their composition, function, and clinical applications.
• Analyze the advantages of component-resolved diagnostics (CRD) in allergy testing, including its impact on precision diagnosis and personalized patient management.
• Assess allergen cross-reactivities with a focus on clinical implications in allergy diagnosis.
• Apply risk assessment strategies for peanut allergies using component-resolved diagnostics to improve patient outcomes and treatment decisions.

Lunch Workshop 8
Room B – 13.00/14.00

TITLE: Bridging Science and Practice: MDW’s Role in Improving Sepsis Outcomes

CHAIR: Elena Sukhacheva, Medical Director
Affiliation: Beckman Coulter Eurocenter; Nyon, Switzerland
SPEAKER 1: Professor Ferdinando Mannello
Affiliation: University “Carlo Bo” of Urbino, Urbino, Italy
SPEAKER 2: Sorbonne-Université GRC-14 BIOFAST
Université de Bordeaux, CHU Pellegrin, Bordeaux, France

PROGRAMME:
-13:00-13:05: welc “Science Behind Monocyte Distribution Width (MDW): Biological Mechanisms of MDW Changes in Sepsis” – Ferdinando Mannello
-13:25 PM – 13:50 PM:  Title of the presentation: “Clinical Impact of the MDW Implementation in the Emergency Department” – *TBD
-13:50 PM – 14:00 PM: Q&A

Learning Objectives:
After attending this workshop, participants will be able to describe the role of monocytes in sepsis and biological mechanisms resulting in MDW changes in sepsis. They also will be able to summarize the clinical impact of MDW implementation in the emergency department as part of patient triage and assessment in routine clinical practice.

Lunch will be served: A Transfer of Value will be reported in regions where transparency/disclosure rules apply.

Lunch Workshop 10
Room 1123 – 13.00/14.00

TITLE: Advancing Immunoassay Innovations: Shedding New Light on Endocrine Diagnostics
CHAIR: Prof. Christa Cobbaert

Affiliation: Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands
SPEAKER 1: Dr. Michael Fahie-Wilson
Affiliation: Department of Clinical Chemistry, Southend Hospital, Westcliff-on-Sea, UK
SPEAKER 2: Prof. Sergio Bernardini
Affiliation: Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy

PROGRAMME:
-13.00-13.05 Welcome and Introduction of the topic and speakers – C. Cobbaert
-13.05-13.30 A Targeted Change on Binding Site: Exploring a New PRL Assay to Reduce Misdiagnosis of Hyperprolactinemia Caused by Macroprolactin Interference. – M. Fahie-Wilson
-13.30-13.55 How Close Can Immunoassays Get to Mass Spectrometry? Investigating a High-Sensitivity Estradiol Immunoassay for Breast Cancer Therapy and Early Pubertal Assessment. –  Prof. Sergio Bernardini
-13:55-14:00 Q&A and close

Learning Objectives:
Accurate hormone measurement is a cornerstone of effective clinical care in oncology, endocrinology and women’s health. However, diagnostic challenges such as macroprolactinemia interference and the need for high-sensitivity detection methods often lead to misdiagnosis or suboptimal monitoring. This workshop addresses these critical issues by exploring innovative advancements in hormone assays, including novel PRL immunoassays with antibodies with optimized binding sites and new sandwich high-sensitivity E2. These technologies hold transformative potential for improving diagnostic precision, enabling better therapeutic management in breast cancer, enhancing reproductive health care, and supporting the monitoring of developmental milestones in pediatric endocrinology.

• Identify and address diagnostic challenges associated with macroprolactin interference in prolactin measurements.
• Explore how a change in antibody binding sites can achieve the anti-macroprolacin interference and enhance the performance of a new PRL immunoassay to reduce hyperprolactinemia misdiagnosis.
• Recognize challenges related to insufficient sensitivity in current estradiol (E2) assays.
• Assess how high-sensitivity estradiol immunoassays compare to mass spectrometry and current immunoassays in terms of sensitivity and accuracy for effective breast cancer therapy monitoring and early pubertal assessment.

Educational Workshop 11
Room Auditorium 500 – 14.30/15.30

TITLE: Layers of Success: New Perspectives on Laboratory Automation

CHAIR: Maros Heidinger
Affiliation: Workflow consulting, Sysmex Europe SE
SPEAKER 1: Dr. Erhan Palaoğlu, Title: Director of Clinical Laboratory
Affiliation: Koç University Hospital, Istanbul
SPEAKER 2: Anja de Jong, Advisor quality test method and Laboratories
Affiliation: Bevolkingsonderzoek Nederland (Health Screening Netherlands), Utrecht, NL
SPEAKER 3: Johanna Engelage
Affiliation: Clinical flow cytometry, Sysmex Europe SE

PROGRAMME:

-14:30-14:35; Introduction – Maros Heidinger
-14:35-14:50: Automation Solutions for Colorectal Cancer Screening with the National Healthcare Screening Programme – Anja de Jong
-14:50-15:05: Shared Knowledge, Smarter Workflows: Driving Efficiency Through Collaboration – Dr. Erhan Palaoğlu
-15:05-15:20: From workflow to decision: Enhancing Flow Cytometry with smart automation – Johanna Engelage
-15:20-15:30 All Q&A

Learning Objectives: Laboratory workflows are dynamic ecosystems composed of interconnected layers, each designed to address specific operational needs within the lab. These layers range from the instruments and processes that facilitate efficient testing to the analytical and information flows that enable precise and timely clinical decision-making. Together, they form an integrated system that supports the critical mission of guiding physicians in treating their patients. At the heart of this interconnected workflow lies the patient journey, where every step plays a pivotal role in ensuring quality care. This symposium will bring together a multidisciplinary team to present real-world examples, illustrating how tailored workflow automation can enhance efficiency, accuracy, and clinical impact. By participating in this session, you will:
1. Understand the multifaceted nature of laboratory workflows.
2. Gain insights from real-life applications
3. Focus on patient-centric innovation
4. Uncover opportunities for optimisation

Educational Workshop 12
Room A – 14.30/15.30

TITLE: Innovation in Internal & External Quality Control in Medical Labs: Use of Bayesian Statistical Methods
CHAIR1: Dr. Piet Meijer, ECAT foundation, External Quality Assessment, Voorschoten, The Netherlands
CHAIR2: Professor Mario Plebani, Padova University Hospital, Padova, Italy
Affiliation: ECAT foundation, External Quality Assessment, Voorschoten, The Netherlands
SPEAKER 1: Prof. Panagiotis Tsiamyrtzis
Affiliation: Department of Mechanical Engineering, Politecnico di Milano, Italy & at the Department of Statistics, Athens University of Economics and Business, Greece
SPEAKER 2: Dr. Frédéric Sobas
Affiliation: Haemostasis Department, Hospices Civils de Lyon, Lyon, France

PROGRAMME:
-14.30-15.00: Bayesian inference vs conventional inference for QC results management
-15.00-15.30: Use of HemoHub Bayesian tools for the management of analytical risks thus for the benefit of the patients

Learning Objectives:
1. Understand the goal of a QC plan to ensure accurate and reliable test results.
2. Apply SPC/M methods to detect process issues.
3. Differentiate between Control and Monitoring:
o Control: Detecting significant transient shifts.
o Monitoring: Identifying persistent structural changes.
4. Explore traditional and Bayesian approaches in QC plans.
5. Evaluate the strengths and weaknesses of these approaches.

Educational Workshop 13
Room B – 14.30/15.30

TITLE: Insights into next-generation high-sensitivity troponin assays
CHAIR: Prof. Kristin Aakre
Affiliation: Department of Clinical Science, University of Bergen/Haukeland University Hospital, Chair of the IFCC Committee of Clinical Application of Cardiac Bio-markers
SPEAKER 1: Dr. Steven Meex
Affiliation: Head of the unit general clinical chemistry and hematology of the Central Diagnostic Laboratory of Maastricht UMC
SPEAKER 2: Dr. med. Pedro Lopez Ayala
Affiliation: Research Fellow at the Cardiovascular Research Institute Basel (CRIB) at University Hospital of Basel

Preliminary PROGRAMME
● 14:30-14:55 Introduction of a new cTnT hs assay (20 min ppt+ 5 min Q&A)
● 14:55-15:15 Clinical performance of a new cTnT hs assay (15 min ppt+ 5 min Q&A)
● 15:15-15:30 Panel discussion and final Q&A ( 15 min)

Learning Objectives:
Disclaimer: Medical can provide and distribute specific Pipeline information (e.g. performance), Pre-Approval Product Information and Off-label Information only at scientific or non-promotional events/meetings such as e.g. congresses, symposia, advisory boards, investigator meetings, subject to applicable local laws and regulations, applicable industry codes and further specific Roche guidance. Information must be fair and balanced, neutral in tone and appearance, non-promotional and compliant with any applicable policies.
By attending this symposium, participants will:
1. Understand assay development and analytical data:
○ Gain insights into the development process and new characteristics of the high-sensitivity cardiac troponin T (cTnT hs) assay, including analytical data and analytical performance metrics.
2. Evaluate preliminary clinical performance from an external cohort:
○ Review and assess preliminary data on the clinical performance of the new TnT hs assay, understanding its potential impact on patient care and diagnostic processes.
3. Engage in expert discussions:
○ Participate in a panel discussion and Q&A session to address questions, share insights, and explore the practical applications of the new cTnT hs assay in clinical settings.

Educational Workshop 15
Room 1123 – 14.30/15.30

TITLE: Emergence of Artificial Intelligence: Transforming Laboratory Workflow of Immunotyping Interpretation in Myeloma

CHAIR: Nathalie Sassine (France)
Affiliation: Myeloma Marketing Group Manager, Sebia
SPEAKER 1: Georges NOUADJE (France) – Sr R&D Director, Sebia
Affiliation: Vice President R&D, Sebia
SPEAKER 2: Dirk Hempel (Germany)
Affiliation: Head of Lab. Onkologisches Zentrum Freising MVZ GmbH, Haemalab

PROGRAMME:
-Introduction – 5min
-Introducing Deep Learning in Immunotyping Interpretation – G. Nouadje (France) -20 min
-Prospective evaluation of of Sebia AI -IT tool in predicting Immunotyping result – Prof. D. Hempel (Germany) – 20min
-Discussion – 15min

Learning Objectives:
• Understand the interest of AI in the routine of Immunotyping interpretation in myeloma
• Describe current Sebia AI -IT tool Analytical Performance and future evolutions
• Learn more about Sebia AI -IT tool benefit in laboratory routine in terms of workflow and operational benefit

Educational Workshop 16
Room Auditorium 500 – 16.00/17.00

TITLE: Clinical Applications of LiCA® Plasma Biomarkers: Advancing Diagnosis and Staging of Alzheimer’s Disease”

CHAIR: Ms. Haijuan Yang
Affiliation: International Business Manager of Chemclin Diagnostics Co., Ltd.
SPEAKER 1: Ms. Yuhui Liu
Affiliation: CTO of Chemclin Diagnostics Co., Ltd.
SPEAKER 2: Ms. Lin Huang – Doctor, Department of Gerontology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University
Affiliation: Invited by Chemclin Diagnostics Co., Ltd.

PROGRAMME:
Speaker 1: Assessing the Efficacy of LiCA® Plasma Biomarker Immunoassays in Detecting Amyloid Pathology: Insights from a Chinese Cohort Study – 30 mins
Speaker 2: Chinese preclinical Alzheimer‘s disease study: Design and preliminary findings – 30 mins

Learning Objectives:
1. Preclinical Alzheimer’s Disease Research:
Analyze real-world data from large cohort studies to evaluate the effectiveness of plasma biomarkers in predicting amyloid pathology and disease progression.
2. Clinical Applications:
Understand the practical implications of integrating LiCA® technology into clinical workflows for high-throughput, accurate, and efficient Alzheimer’s disease diagnosis.
3. Understanding LiCA® Technology:
Gain insights into the working mechanism, the performance and clinical utility of LiCA® plasma biomarker immunoassays in detecting amyloid pathology.

Educational Workshop 17
Room A – 16.00/17.00/h3>

TITLE: Unlocking the Potential of Real-World Evidence for IVDs: Opportunities for Laboratories and Manufacturers

CHAIR: Iana Slobodeaniuc, Senior Manager IVDR
Affiliation: MedTech Europe
SPEAKER 1: Ramya Bhatia PhD, Associate Director, Clinical Affairs
Affiliation: Qiagen
SPEAKER 2: Nathalie De Vos, Clinical biologist at LHUB-ULB chemistry core lab, medical responsible for point-of-care testing

PROGRAMME:
-The Industry perspective: regulatory contraints, existing possibilities and vision for the future (15 min)
-Unlocking the Potential of Real-World Data: Opportunities for Laboratories (20 min)
-Q&A (20 min)

Learning Objectives:
1 – Introduce the concept of Real-World Evidence (RWE), which is generated from Real-World Data (RWD). RWD includes patient and device information derived from sources other than traditional controlled studies or clinical trials
2 – The workshop will highlight the potential of RWE in the context of the In Vitro Diagnostic Regulation (IVDR) and provides examples of how RWE can support evidence generation for In Vitro diagnostics (IVDs) for Laboratories and the industry

Educational Workshop 18
Room B – 16.00/17.00

TITLE: Improved Leukaemia Diagnostic Pathway: The Role of Digital Morphology

SPEAKER 1: Professor Gina Zini
Affiliation: Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS

Learning Objectives:
1. Using morphology to identify the leukemia cell line, determine the stage of differentiation of the leukemia cell, diagnose acute leukemia by examining blood smears or bone marrow, and subtype leukemia, such as acute myeloid leukemia (AML).
2. Improving the leukaemia diagnostic process through the utilization of the Scopio Imaging Platform System with Bone Marrow Application, and the Atellica HEMA 580 Hematology System.

Educational Workshop 20
Room 1123 – 16.00/17.00

TITLE: one toch sample handling, how innovative sample shipping can significantly shorten the time to result, save resources and as with excellent sample quality
CHAIR: Prof. Dr. med. Matthias Nauck
Universitätsmedizin Greifswald – Institut für Klinische Chemie und Laboratoriumsmedizin

SPEAKER 1: Prof. Dr. med. Matthias Nauck
Universitätsmedizin Greifswald – Institut für Klinische Chemie und Laboratoriumsmedizin

SPEAKER 2: Daniel Blak
CEO SARSTEDT ApS – DK-7441 Bording

SPEAKER 3: Christian Schläpfer
CEO katena GmbH – CH-8104 Weiningen

PROGRAMME:

-Speaker 1: 20 minutes – Faster diagnoses through innovative tube transport systems: 10 years of experience
-Speaker 2: 10 minutes – Revolutionising hospital logistics: Tempus1800® delivers faster and gentler transport of small clinical samples, even over long distances

-Speaker 3: 20 minutes – Optimizing laboratory logistics: seamless integration of pre-analytical processes for greater efficiency and sample quality at the University Hospital Zurich (USZ)
-Final Discussion: 10 minutes

Learning Objectives:
The presentations will use case studies and innovative technologies to show how to optimize the sample workflow with fast and gentle sample transport, protect human resources and significantly reduce the time to analysis results.

Lunch Workshop 9 – EDUW14 – EDUW19
Room C – 13.00/17.00

TITLE: THE ROLE OF BIOMARKERS IN LABORATORY MEDICINE
SESSION ONE
CHAIR 1: Dr. Gizachew Taddesse Akalu
Affiliation: Assistant Professor of Microbial, Cellular and Molecular Biology, Department of Microbiology, Immunology and Parasitology, School of Medicine, St. Paul’s Hospital Millennium Medical College – Research Coordinator, Research Development Directorate, St. Paul’ s Hospital Millennium Medical College – President, African Federation of Clinical Chemistry (AFCC)
SPEAKER 1: Prof. Maurizio Ferrari
Affiliation: Full Professor of Clinical Pathology – Former President of IFCC – Synlab Italy
SPEAKER 2: Prof. Harald Renz
Affiliation: Director and Chairman of the Institute of Laboratory Medicine and Pathobiochemistry of the Philipps-University Marburg – President of The German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL)
SPEAKER 3: Dr. Fayha Salah Ahmed
Affiliation: Consultant Pathologist, Division Chief of Clinical Chemistry, Immunology & POCT. Dubai Health, U.A.E. – Vice-President Emirates Clinical Chemistry Society
SPEAKER 4: Dr. Leslie Lam
Affiliation: President, Singapore Association of Clinical Biochemists(SACB) – Deputy Medical Director & Consultant Chemical Pathologist, Parkway Laboratories – Chair, POCT Committee, Parkway Hospitals

SESSION TWO
CHAIR 2: Dr. Mouza Abdulla AlSharhan
Affilaition: Consultant & Head of Pathology, Dubai Hospital – Dubai Health, UAE – President of Emirates Pathology Society, UAE – Former President, Emirates Medical Association, UAE
SPEAKER 5: Prof. Etienne Cavalier
Affiliation: Head of the Department of Clinical Chemistry of the University and CHU of Liège, Belgium – President of the Royal Belgian Society of Laboratory Medicine – Chairman of the EFLM Committee of Chronic Kidney Diseases (C-CKD) – Chairman(2019-2024) of the IFCC Committee for Bone Metabolism (C-BM) – Vice-Chair of the International Osteoporosis foundation (IOF) Committee of Scientific Advisors
SPEAKER 6: Dr. Laila AbdelWareth
Affiliation: CEO, National Reference Laboratory, M42, UAE – CEO, Diagnostics, Global Patient Care, M42, UAE – President, Emirates Clinical Chemistry Society, UAE
SPEAKER 7: Dr. Leonardo Vedolin
Affiliation: Executive vice president and Chief Medical Officer, Dasa, Brazil

SPEAKER 8: Dr. Alap Christy
Affiliation: Vice President & Scientific Business Head-Clinical Chemistry, Metropolis Healthcare Limited, India – MBBS, MD, PGDM Healthcare Management, SMP – Member of ADLM, EFLM, AMBI, ACCLMP, TPA – Alumni, Indian Institute of Management Kozhikode & Manipal University
SPEAKER 9: Dr. Osama Najjar
Affiliation: Past President of Arab Federation of Clinical Biology (AFCB) – President of Palestinian Medical Technology Association (PMTA) – Assistant Deputy of Allied Health Professions Ministry of Health (MOH), Palestine

PROGRAMME:
SESSION ONE

-13:00-14:45 – Chair – Dr. Gizachew Taddesse Akalu
-13:05-13:30 Aging and Big Data: New Trends in Laboratory Medicine – Prof. Maurizio Ferrari
-13:30-13:55 Use Case Inflammation and Sepsis: The Increasing Role of Laboratory Medicine – Prof. Harald Renz
-13:55-14:20 The Burden of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Screening, Diagnosis, and Management – Dr. Fayha Salah Ahmed
-14:20-14:45 Practical Solutions to Common Interferences in Immunoassay Testing – Dr. Leslie Lam

SESSION TWO

-14:45-16:55 – Chair – Dr. Mouza Abdulla AlSharhan
-14:50-15:15 Update on 25-OH Vitamin D Measurement and Metabolites – Prof. Etienne Cavalier
– 15:15-15:40 Decoding Alzheimer’s Disease: The Promise of Blood-Based Biomarkers – Dr. Laila AbdelWareth
-15:40-16:05 Big Data in Diagnostic Medicine – Dr. Leonardo Vedolin
-16:05-16:30 Congenital Adrenal Hyperplasia – the Chemistry of Dilemma – Dr. Alap Christy
-16:30-16:55 Biomarkers of Acute Kidney Injuries – Dr. Osama Najjar

Learning Objectives:

• After the lecture you will have a clear view of the future of laboratory medicine related to aging.
• You will learn the significance of Big Data related to laboratory medicine.
• You will learn the concept of biological versus chronological age, the hallmarks of aging, and the importance of laboratory
• Discuss the epidemiology & risk factors for Alzheimer’s Disease (AD)
• Illustrate the various biomarkers used for the diagnosis of AD
• Identify the applications of Blood Based Biomarkers (BBB) for the diagnosis and risk stratification of AD
• Explore the Role of CLIA in Diagnosing Congenital Adrenal Hyperplasia (CAH):Understand how CLIA-based assays can effectively detect key biochemical markers for CAH, offering reliable alternatives to LC-MS/MS.
• Apply Case-Based Learning to Interpret CLIA Results: Analyze and discuss real-world case studies where CLIA technology provided accurate and actionable diagnostic insights for managing CAH.
• Highlight Practical Advantages of CLIA in Clinical Practice: Compare the clinical utility, accessibility, and cost-effectiveness of CLIA versus advanced technologies like LC-MS/MS in routine and complex scenarios of CAH diagnosis.
• Understand the evolution of terminology from NAFLD to MASLD: Participants will learn the rationale behind the shift in nomenclature, the criteria for diagnosis under the MASLD framework, and its implications for patient care.
• Explore diagnostic and management strategies for MASLD: The presentation aims to familiarize attendees with non-invasive diagnostic tools, the role of biomarkers, and emerging therapeutic options for effective management of MASLD.
• Recognize the public health impact of MASLD: Participants will grasp the economic and healthcare burden posed by MASLD and the importance of implementing preventive strategies such as lifestyle modifications and early screening.
• Understand the Metabolism of Vitamin D – Explain the synthesis, metabolism, and different forms of vitamin D, including the role of UVB radiation, liver, and kidney enzymes in producing 25(OH)D and 1,25(OH)2D.
• Evaluate Vitamin D Measurement Techniques – Compare the advantages and limitations of different vitamin D measurement methods, including immunoassays and LC-MS/MS, and understand the significance of assay standardization.
• Interpret Clinical Cases Involving Vitamin D – Analyze real-world clinical cases to identify vitamin D deficiencies, toxicities, and disorders linked to genetic mutations affecting vitamin D metabolism (e.g., CYP24A1 defect).
• Recognize the Importance of Vitamin D Standardization – Explain the ongoing efforts and challenges in standardizing vitamin D assays (e.g., VDSP, DEQAS) to ensure accuracy and consistency in clinical practice.
• To learn about the physiology of inflammation and sepsisù
• To learn about key biomarkers presenting the most important corner stone’s inflammation and sepsis
• To learn about the sensitivity and specificity and clinical use in clinical routine and health settings.
• Identifying and differentiating various biomarkers associated with AKI
• Analyzing the role of biomarkers in prognosis and management
• Evaluating the diagnosis utility and limitations of specific biomarkers associated with AKI

Lunch Workshop 12
Room A – 13.00/14.00

TITLE: Patient blood management

CHAIR: Ana-Maria Simundic, Director Global Medical & Clinical Affairs
Affiliation: Greiner Bio-One, Austria
SPEAKER 1: Ana-Maria Simundic, Director Global Medical & Clinical Affairs
Affiliation: Greiner Bio-One, Austria
SPEAKER 2: Michael Cornes, Consultant Clinical Scientist & Pathology Clinical Director
Affiliation: Worcestershire Acute Hospitals NHS Trust, UK

PROGRAMME:
1. Introduction to PBM – what is PBM and why is it important? (25 min)
2. Patient-, cost- and sustainability-related outcomes of PBM interventions: case study (25 min)
3. Q&A and Discussion (10 min)

Learning Objectives:
• To understand the extent and consequences of excessive and unnecessary patient blood loss
• To learn about ways to minimize patient blood loss
• To understand how some patient-, cost-, and sustainability-related benefits can be achieved through implementing PBM interventions

Lunch Workshop 13
Room B – 13.00/14.00

TITLE: K+ measurement in Blood Gas Analysis: a hidden risk for patient outcome. The role of Hemolysis

CHAIR 1: Dr. Romy Gadisseur, Clinical chemistry Laboratory, CHU Liège, Sart-Tilman, Belgium
CHAIR 2: Professor Mario Plebani, Padova University Hospital, Padova, Italy
Affiliation: Clinical chemistry laboratory, CHU Liège, Sart-Tilman, Belgium
SPEAKER 1: Dr. Robert Slingerland
Affiliation: Clinical chemistry laboratory, Isala Hospital, Zwolle, The Netherlands
SPEAKER 2: Prof. Manuel Sánchez Luna
Affiliation: Neonatology and NICU Division, Hospital General Universitario “Gregorio Marañón”, Madrid, Spain

PROGRAMME:
-14.30-15.00: Impact of Hemolysis on POCT K+ measurement. The Lab perspective
-15.00-15.30: K+ measurement in NICU settings – risks and opportunities for improvement

Learning Objectives:
1. Understand the importance of K+ measurement in clinical and laboratory settings.
2. Interpret K+ measurement results and their clinical significance.
3. Define quality control procedures and solutions to ensure reliable K+ measurement at POC

Lunch Workshop 15
Room 1123 – 13.00/14.00

TITLE: What’s new in the preanalytical “toolbox” for challenging environments?

CHAIR: Dr Antonio Buño Soto
Head of Laboratory Medicine Department. Hospital Universitario La Paz. Madrid. Spain
Speaker 1: Dr Raül Santamaria Merino
Laboratory Deputy Director, Catlab, Barcelona, Spain
Speaker 2: Dr Settar Kosova
Laboratory Director, Çaycuma State Hospital, Çaycuma, Turkey
Speaker 3: Prof Andrea Padoan
Associate Professor of Clinical Biochemistry and Molecular Biology, University-Hospital of Padova, Italy

PROGRAMME:
-Introduction – Antonio Buño Soto – 5 min
-Talk 1: Accrediting the preanalytical phase in primary and secondary care: Experience of a central laboratory – Raül Santamaria Merino – 15min
-Talk 2: A Preanalytical Quality Check and Training Program to effectively reduce preanalytical errors in a hospital setting – Settar Kosova – 15min
-Talk 3: Overcoming challenges in blood collection for difficult venous access: exploring preanalytical innovations – Andrea Padoan – 15min
-Q&A – 10min

Learning objectives
• Understand the Impact of Preanalytical Errors: Analyze the current state of preanalytical errors and their implications for laboratory accuracy and patient care.
• Explore Innovative Tools for Workflow Optimization: Evaluate the capabilities of the preanalytical quality check tools for monitoring and tracking preanalytical processes in primary care and hospital environments.
• Address Challenges in Venous Access: identify strategies and technologies for managing difficult venous access in hospitals to minimize preanalytical errors and improve sample quality.
• Promote Best Practices in Preanalytics: discuss actionable steps and practical approaches to reduce variability and enhance reliability in the preanalytical phase across challenging healthcare environments.

Educational Workshop 21
Room Auditorium 500 – 14.30/15.30

TITLE: Autoimmunity and Reproductive Health

CHAIR: Tommaso Trenti
Affiliation: Chief Scientific Officer of Bianalisi
SPEAKER 1: Savino Sciascia
Affiliation: University of Turin
SPEAKER 2: Emanuele Bosi
Affiliation: Università Vita-Salute San Raffaele
SPEAKER 3: Prof. Pietro Formisano
Affiliation: University of Naples “Federico II”

PROGRAMME:
1. Prof. Sciascia – Theme: Anti-Phospholipid Syndrome (15 min)
2. Prof. Emanuele Bosi – Theme: Screening of Type 1 Diabetes (15 min)
3. Prof. Formisano – Theme: Scientific study about 17α-OH-P (15 min)

Learning Objectives:
These presentations aim to promote our new biomarkers by taking advantage of the influence of KOLs. Meanwhile, we hope to promote our advanced technology by marketing these new biomarkers.

Educational Workshop 22
Room A – 14.30/15.30

TITLE: Hemolysis – can we do it better?

CHAIR: Ana-Maria Simundic, Director Global Medical & Clinical Affairs
Affiliation: Greiner Bio-One, Austria
SPEAKER 1: Ana-Maria Simundic, Director Global Medical & Clinical Affairs
Affiliation: Greiner Bio-One, Austria
SPEAKER 2: Jeff W. Meeusen
Affiliation: Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA

PROGRAMME:
1. Understanding the physics of blood collection (25 min)
2. Smart blood collection – how to avoid hemolysis? (25 min)
3. Q&A and Discussion (10 min)

Learning Objectives:
• To understand mechanisms through which blood collection may lead to hemolysis
• To understand the relationship of shear forces and hemolysis
• To learn ways to avoid hemolysis

Educational Workshop 13
Room B – 14.30/15.30

TITLE: Enhancing Autoimmunity Lab Efficiency with Particle-Based Multi-Analyte Technology

CHAIR: Dr Laura Martiez-Prat, Autoimmunity Global Scientific Affairs Manager, Werfen, Barcelona, Spain
Affiliation: Vice President Commercial Operations Europe, Werfen, Barcelona, Spain
SPEAKER 1: D.ssa. Stefania Del Rosso
Affiliation: Autoimmunity laboratory, Ospedale San Reffaele, Milan, Italy
SPEAKER 2: Dr. Vincent Ricchiuti
Affiliation: LabCorp, Dublin OH, USA

PROGRAMME:
-14.30-15.00: Particle-based Multi-Analyte Technology (PMAT): a new frontier for the Autoimmunity Lab
-15.00-15.30: Improving end-to-end workflow in the Autoimmunity lab: practical perspectives

Learning Objectives:
1. Identify ways to streamline laboratory workflows to enhance efficiency and reduce bottlenecks.
2. Explore the benefits of multiplexing in autoimmunity testing to reduce time to results and improve accuracy.
3. Improve process control in the lab to ensure consistent and reliable results.
4. Discover strategies for automating manual tasks to increase efficiency and reduce human error.
5. Make laboratory practices more sustainable by reducing waste and optimizing resource use.
6. Implement changes to significantly reduce the time it takes to obtain results, improving patient care and lab productivity

Educational Workshop 25
Room 1123 – 14.30/15.30

TITLE: A Patient-Outcome Approach to Sepsis Biomarkers: Promising Leads and Proven Performers

CHAIR: Pr. Matteo Vidali
Affiliation: Director of Pathology Unit, Fondazione IRCCS Cà Granda, Policlinico Hospital, Milan, Italy
SPEAKER 1: Pr. Christos Tsatsanis
Affiliation: Professor of Clinical Chemistry, Medical School, University of Crete
SPEAKER 2: Pr. Evangelos Giamarellos-Bourboulis
Affiliation: 4th Department of Internal Medicine, Director MSc Infectious Diseases, National & Kapodistrian University of Athens, Greece

PROGRAMME:
-14:30 – 14:35 Introduction – Pr. Matteo Vidali
-14:35 – 14:55 Overview of the current landscape of sepsis biomarkers – Pr. Christos Tsatsanis
-14:55 – 15:15 Evidence-based Insights Into Sepsis Biomarkers
-15:15 – 15:30 Q&A session
• Overview of biomarkers applied to sepsis endotype classification.
• Procalcitonin to guide antibiotic treatment: evidence from clinical trials.
– Pr. Evangelos Giamarellos-Bourboulis

Learning Objectives:
• Identifying the key biomarkers being used and researched in the diagnosis and management of sepsis.
• Interpreting the clinical significance of biomarkers according to evidence on patient outcomes.
• Understanding the role of procalcitonin guiding antibiotic therapy and its linkage to clinical outcomes in sepsis.

Lunch Workshop 14 – EDUW24 – EDUW29
Room C – 13.00/17.00

TITLE: LATEST UPDATES IN LABORATORY MEDICINE
SESSION ONE
CHAIR 1: Prof. Katerina Tosheska Trajkovska
Affilaition: Full Professor of Biochemistry and Clinical Biochemistry, Medical Faculty, University “Ss Cyril and Methodius”, Skopje, R. North Macedonia – Specialist in Medical Biochemistry, EuSpLM – President of MSMBLM – Head of Institute of Medical and Experimental Biochemistry, Medical Faculty, University “Ss Cyril and Methodius”, Skopje, North Macedonia – IFCC & BCLF National Representative
SPEAKER 1: Prof. Khosrow Adeli
Affiliation: Past President, International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) – Head, Clinical Biochemistry, Paediatric Laboratory Medicine, SickKids – Senior Scientist, Molecular Medicine Program of the Research Institute, SickKids – Full Professor, Laboratory Medicine and Pathobiology (LMP), Biochemistry and Physiology, University of Toronto, Canada
SPEAKER 2: Prof. Vincent Sapin
Affiliation: Professor University Hospital of Clermont-Ferrand, France – Head of Biochemsitry and Molecular Genetics Department at University Hospital of Clermont-Ferrand – France SFBC Past-President – President of International Francophonie Federation of Clinical Biology and Laboratory Medicine – Coordinator of the EFLM Working Group « mTBI Biomarkers »
SPEAKER 3: Prof. Olga Ciepiela –
Affiliation: Full Professor of Medical and Health Sciences – Head of Clinical Laboratory of University Clinical Center of Medical University of Warsaw – Deputy Dean of Faculty of Pharmacy for Education of Laboratory Medicine Students – Member of IFCC Task Force on Laboratory Medicine Practice Guidelines (TF-LMPG) – Executive Committee’s Member of the EFLM Division “Science: Value-Based Laboratory Medicine”
SPEAKER 4: Prof. Damien Gruson
Affiliation: Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium – Research Unit of Endocrinology, Diabetes and Nutrition, UCLouvain – Chair of the IFCC Division on Emerging Technologies – Member of the RBSLM Board of Directors – Member of the SFBC Board of Directors – Fellow of the ESC and Fellow of the HFA

SESSION TWO
CHAIR 2: Prof. A.A. Wiradewi Lestari
Affilaition: Clinical Pathologist and Academic Professor Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana Ngoerah Hospital Bali, Indonesia – Executive Board Member of Indonesian Association for Clinical Chemistry – Head of Genomics Section, Integrated Laboratory, Ngoerah Hospital Bali, Indonesia – President, Indonesian College of Clinical Pathology

SPEAKER 5: Dr. Endang Hoyaranda
Affiliation: APFCB Immediate past president – IACC Board Member – The President Director of Prodia Group Holding Company
SPEAKER 6: Prof. Minodora Dobreanu
Affiliation: Vice presidentof AMLR (Romanian Associationof Laboratory Medicine) – Head of Department of Laboratory Medicine, Emergency Clinical County Hospital, Targu Mures, Romania – Full Professor, Department of Laboratory Medicine,”George Emil Palade” University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania
SPEAKER 7: Dr. Sjoerd A.A. Van Den Berg
Affiliation: Laboratory Director (EUSpLM) at Erasmus MC, Rotterdam, The Netherlands – Endocrinologist – Diagnostic Endocrinology Researcher
SPEAKER 8: Dr. Guillermo Santoscoy Ascencio
Affiliation: Clinical Pathologist – Doctor of Science in Molecular Biology in Medicine – President of the Mexican Federation of Clinical Pathology (FEMPAC) – Chief of the Molecular Diagnostics Department, Unidad de Patologia Clinica, Guadalajara, Mexico – CAP Inspector
SPEAKER 9: Dr. In Fong LAM
Affiliation: Specialist in Clinical Pathology, Centro Hospitalar Conde de São Januário (CHCSJ), Macao – Fellow of Pathology Faculty, Macao Academy of Medicine – Member of Council, Infection Control Association of Macao – Member, Macao Laboratory Medicine Association – Member, Macao Health Bureau Doctor’s Association – Member, Macao Physician Society

PROGRAMME:
SESSION ONE

-13:00-14:45 – Chair – Prof. Katerina Tosheska Trjkovska
-13:05-13:30 Pediatric Laboratory Medicine: Innovations and New Insights for Optimal Child Health – Prof. Khosrow Adeli
-13:30-13:55 Blood Biomarkers of Mild Traumatic Brain Injury: Focus on S100B Protein – Prof. Vincent Sapin
-13:55-14:20 Cardiovascular Markers for Monitoring the Dietetic Intervention in Obese and Overweight Patients – Prof. Olga Ciepiela
-14:20-14:45 Cardiovascular Readiness: From Early Detection to Enhanced Prevention – Prof. Damien Gruson

SESSION TWO

-14:45-16:55 – Chair – Prof. A. A. Wiradewi Lestari
-14:50-15:15 How Medical Laboratories Can Maximize Contribution to Sustainability – Dr. Endang Hoyaranda
-15:15-15:40 Diagnostic Approach in Common Autoimmune Disease – ‘Choosing Wisely’ the Serological Tests – Prof. Minodora Dobreanu
-15:40-16:05 Thyroid Hormone Measurements; More Than T3 and T4 – Dr. Sjoerd A.A. Van Den Berg
-16:05-16:30 The Impact of Molecular Diagnostics in Cancer Screening, Diagnosis and Prognosis  – Dr. Guillermo Santoscoy Ascencio
-16:30-16:55 Human Leukocyte Antigens Associated Drug Hypersensitivity – Dr. In Fong LAM

Learning Objectives:

• Understand the Unique Challenges in Pediatric Laboratory Medicine: Describe the physiological differences in children that impact laboratory testing and interpretation and discuss the importance of age- and sex-specific reference intervals for accurate diagnosis and monitoring.
• Explore Innovations in Pediatric Diagnostic Technologies: Review recent advancements in laboratory technologies, including point-of-care testing, genomic medicine, and multiplex assays, and their implications for improving pediatric healthcare outcomes.
• Promote Best Practices in Pediatric Laboratory Testing: Identify strategies to optimize specimen collection, minimize invasive procedures, and enhance the reliability and efficiency of laboratory testing for pediatric patients.
• Understand the Role of Biomarkers in Early Detection: Explore how cutting-edge laboratory tests and biomarkers can identify cardiovascular risks and facilitate timely interventions in clinical practice.
• Integrate Laboratory Medicine in Preventive Strategies: Learn how laboratory diagnostics contribute to personalized prevention programs by linking biochemical findings to lifestyle and therapeutic adjustments.
• Innovate Through Emerging Technologies: Discuss the integration of advanced laboratory technologies, including point-of-care testing and AI, to enhance cardiovascular disease prevention and management workflows
• Place of the blood biomarkers during the management of mild Traumatic Brain Injury’ patients
• Presentation of the current blood biomarkers of the mild Traumatic Brain Injury
• Presentation of S100B and its place for the management of mild Traumatic Brain Injury
• Point out cardiovascular markers used in cardiac risk assessment, which may be modified by dietetic intervention.
• Possess the knowledge regarding use of myeloperoxidase and hFABP as cardiovascular markers.
• Identify biochemical mechanisms that lead to changes in cardiovascular markers concentration in the process of body-mass reduction based on dietetic intervention.
• Leveraging awareness to healthcare practitioners on the urgent need to contribute to sustainability efforts.
• Updating ways on the ways healthcare can contribute
• Severe cutaneous adverse reactions (SCAR) are serious skin reactions often triggered by medications, and genetic predisposition plays a significant role in their development. Specific HLA alleles, such as HLA-B*15:02 and HLA-A*58:01, have been associated with an increased risk of SCARs, particularly in certain populations. Understanding these associations can enhance pharmacogenetic screening, potentially preventing SCARs through personalized medication choices and improving patient safety in drug therapy.
• Interference in immunoassays cannot be assessed by spike experiments only.
• Treatment of patients with thyroid hormone transporter problems requires specific immunoassays or mass-spectrometry.
• Harmonisation and/or standardisation of T3 and T4 assays is still lacking, even though a reference measurement procedure is available.
• T3 is not the only bioactive thyroid hormone.